Core Insights - The conference held by Gushengtang on December 5, 2025, showcased significant collaborations and achievements in the integration of traditional Chinese medicine (TCM) and artificial intelligence (AI), highlighting the company's commitment to modernizing TCM and expanding its international presence [1][3]. Group 1: AI Model Development - Gushengtang announced partnerships with four leading research teams to develop a TCM AI model, enhancing clinical applicability and reliability through interdisciplinary collaboration [7][8]. - The collaboration aims to create a robust AI evaluation system and develop AI applications like the "National Medicine AI Avatar" to assist in diagnosis and patient management [8][9]. Group 2: Clinical Research Integration - A clinical research integration platform was launched to accelerate the transformation of clinical research outcomes, focusing on real-world data evaluation in TCM [10]. - Gushengtang has completed 16 internal formulations, with one product successfully certified and launched in Singapore, demonstrating its strong R&D capabilities [10]. Group 3: Global Expansion and Ecosystem Development - Gushengtang is expanding its service boundaries through a strategic partnership with Amap, integrating TCM services with navigation and local life scenarios to enhance user accessibility [11]. - The company is adopting a "merger + cooperation + self-built" strategy for global expansion, with a full acquisition of Singapore Chinese Medicine to increase its presence in the region [12].

Core Insights - The conference held by Guoshengtang on December 5, 2025, showcased significant collaborations and innovations in the integration of traditional Chinese medicine (TCM) and artificial intelligence (AI) [1][3] - Guoshengtang aims to modernize and internationalize TCM, responding to national policy initiatives and expanding its service capabilities through AI and overseas market development [3] Group 1: Collaborations and Innovations - Guoshengtang announced partnerships with four leading research teams to develop a TCM AI model, enhancing clinical applicability and reliability [6] - The company launched the "National Medicine AI Avatar" product, providing real-time clinical decision support for young doctors, currently in trial operation across several specialties [7] - A clinical research integration platform was initiated to address real-world data evaluation challenges in TCM, with 16 internal formulations already registered [8] Group 2: Global Expansion and Market Strategy - Guoshengtang signed a strategic cooperation agreement with Amap to integrate TCM services with navigation and local life scenarios, enhancing user accessibility [10] - The company is pursuing a "merger + cooperation + self-built" strategy for global expansion, with a full acquisition of Singapore Chinese Medicine to increase its presence in the region [10] - The overall strategy emphasizes AI-driven diagnosis, research-driven products, and a comprehensive flow ecosystem to support TCM's international outreach [10]